Looking to expand your partner network with leading companies like Onxeo? Consider joining Inpart's global network for free.
News and Trends 27 Jan 2023
Onxeo to study prostate cancer drug
French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients […]